MX2022005780A - Moduladores de receptores estrogenicos. - Google Patents
Moduladores de receptores estrogenicos.Info
- Publication number
- MX2022005780A MX2022005780A MX2022005780A MX2022005780A MX2022005780A MX 2022005780 A MX2022005780 A MX 2022005780A MX 2022005780 A MX2022005780 A MX 2022005780A MX 2022005780 A MX2022005780 A MX 2022005780A MX 2022005780 A MX2022005780 A MX 2022005780A
- Authority
- MX
- Mexico
- Prior art keywords
- estrogen receptor
- receptor alpha
- receptor modulators
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
- C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings
Abstract
Los compuestos de la Fórmula (I) son moduladores de receptores estrogénicos alfa, donde las variables de la Fórmula (I) se describen en la descripción. Tales compuestos, así como sales farmacéuticamente aceptables y composiciones de estos, son útiles para tratar enfermedades o afecciones que son dependientes de receptores estrogénicos alfa y/o están mediadas por receptores estrogénicos alfa, que incluyen afecciones caracterizadas por proliferación celular excesiva, tales como cáncer de mama.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317254P | 2016-04-01 | 2016-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005780A true MX2022005780A (es) | 2022-06-09 |
Family
ID=59966438
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011419A MX2018011419A (es) | 2016-04-01 | 2017-03-29 | Moduladores de receptores estrogénicos. |
MX2022005780A MX2022005780A (es) | 2016-04-01 | 2018-09-24 | Moduladores de receptores estrogenicos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011419A MX2018011419A (es) | 2016-04-01 | 2017-03-29 | Moduladores de receptores estrogénicos. |
Country Status (15)
Country | Link |
---|---|
US (5) | US20190142811A1 (es) |
EP (1) | EP3442971A4 (es) |
JP (2) | JP6926189B2 (es) |
KR (2) | KR102401841B1 (es) |
CN (4) | CN113717170A (es) |
AR (1) | AR108011A1 (es) |
AU (3) | AU2017242027B2 (es) |
BR (1) | BR112018070161A2 (es) |
CA (1) | CA3017388C (es) |
IL (3) | IL285318B (es) |
MX (2) | MX2018011419A (es) |
RU (1) | RU2738646C2 (es) |
SG (1) | SG11201807708SA (es) |
TW (2) | TW202235418A (es) |
WO (1) | WO2017172957A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018015419B1 (pt) | 2016-02-05 | 2024-01-30 | Inventisbio Llc | Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica |
KR102401841B1 (ko) | 2016-04-01 | 2022-05-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性***受体下调剂的三环类化合物及其应用 |
EP3665142A4 (en) | 2017-09-11 | 2021-04-28 | Recurium IP Holdings, LLC | CONTINUOUS CURRENT PROCESS FOR THE PRODUCTION OF BICYCLIC CONNECTIONS |
US11179365B2 (en) | 2017-11-16 | 2021-11-23 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and ribociclib |
CN114929696A (zh) * | 2019-05-24 | 2022-08-19 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
AU2020326691A1 (en) * | 2019-08-06 | 2022-03-03 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
KR20220103977A (ko) * | 2019-11-04 | 2022-07-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제의 염 및 형태 |
WO2021127042A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
MX2022007630A (es) * | 2019-12-20 | 2022-08-16 | Recurium Ip Holdings Llc | Combinaciones. |
BR112022012280A2 (pt) * | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
US20230042653A1 (en) * | 2019-12-20 | 2023-02-09 | Recurium Ip Holdings, Llc | Combinations |
CA3165382A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
MX2022012828A (es) * | 2020-04-22 | 2023-01-04 | Recurium Ip Holdings Llc | Preparación de un degradador selectivo de receptores de estrógeno. |
WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
WO2022061242A1 (en) * | 2020-09-20 | 2022-03-24 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
WO2022133446A1 (en) * | 2020-12-16 | 2022-06-23 | Recurium Ip Holdings, Llc | Combinations |
WO2022140744A1 (en) * | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
IL309986A (en) * | 2021-07-08 | 2024-03-01 | Olema Pharmaceuticals Inc | Methods for treating diseases related to estrogen receptors |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU679635B2 (en) | 1994-03-11 | 1997-07-03 | Eli Lilly And Company | Method for treating 5HT-2B receptor related conditions |
GB9604996D0 (en) | 1996-03-08 | 1996-05-08 | Black James Foundation | Benzodiazonine derivatives |
EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
ATE348828T1 (de) | 2001-10-19 | 2007-01-15 | Transtech Pharma Inc | Beta-carbolin-derivate als ptp-inhibitoren |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
EP1786425A1 (en) | 2004-08-02 | 2007-05-23 | SmithKline Beecham Corporation | Useful compounds for hpv infection |
WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
ES2436028T3 (es) | 2006-06-23 | 2013-12-26 | Radius Health, Inc. | Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno |
AU2008239598A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
TW201028414A (en) * | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
CA2999345A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
WO2010138706A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
ES2567328T3 (es) * | 2009-07-28 | 2016-04-21 | Ono Pharmaceutical Co., Ltd. | Compuesto bicíclico y uso del mismo para fines médicos |
CN102695414A (zh) | 2010-01-15 | 2012-09-26 | 默沙东公司 | 作为抗糖尿病化合物的噁二唑β-咔啉衍生物 |
CA2789622C (en) * | 2010-02-11 | 2018-04-03 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
WO2011103487A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | ***受体调节剂及其用途 |
EP2669279B1 (en) * | 2011-01-27 | 2017-01-11 | ONO Pharmaceutical Co., Ltd. | Bicyclic compound and use thereof for medical purposes |
CN102432608B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法 |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
NO2797921T3 (es) * | 2011-12-31 | 2018-02-03 | ||
WO2013119639A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
DK2872482T3 (da) | 2012-07-13 | 2020-09-21 | Oncternal Therapeutics Inc | En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm) |
HUE039052T2 (hu) | 2013-02-19 | 2018-12-28 | Novartis Ag | Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként |
US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
LT3004090T (lt) * | 2013-05-28 | 2018-01-10 | Astrazeneca Ab | Cheminiai junginiai |
AU2014358850A1 (en) | 2013-12-06 | 2016-06-16 | F. Hoffmann-La Roche Ag | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
CN104693211A (zh) | 2013-12-10 | 2015-06-10 | 南京明德新药研发股份有限公司 | 作为抗病毒剂的咪唑衍生物及其制药用途 |
WO2015123355A1 (en) * | 2014-02-12 | 2015-08-20 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
WO2015171527A1 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
CA2948077A1 (en) | 2014-05-16 | 2015-11-19 | Actelion Pharmaceuticals Ltd | Antibacterial quinazoline-4(3h)-one derivatives |
CN106536520B (zh) | 2014-06-27 | 2020-08-14 | 诺格拉制药有限公司 | 芳基受体调制剂及其制备和使用方法 |
AU2015330490B2 (en) | 2014-10-09 | 2018-08-09 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and applications thereof |
US9814698B2 (en) | 2015-04-21 | 2017-11-14 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
MX2017016376A (es) * | 2015-06-16 | 2018-03-02 | Jiangsu Hengrui Medicine Co | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. |
US10519148B2 (en) | 2015-11-12 | 2019-12-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
BR112018015419B1 (pt) * | 2016-02-05 | 2024-01-30 | Inventisbio Llc | Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica |
KR102401841B1 (ko) | 2016-04-01 | 2022-05-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
KR102481319B1 (ko) | 2016-06-10 | 2022-12-26 | 유니버시티 오브 테네시 리서치 파운데이션 | 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법 |
WO2018001232A1 (zh) * | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
CN110139674B (zh) * | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性***受体下调剂的三环类化合物及其应用 |
-
2017
- 2017-03-29 KR KR1020187030841A patent/KR102401841B1/ko active IP Right Grant
- 2017-03-29 MX MX2018011419A patent/MX2018011419A/es unknown
- 2017-03-29 SG SG11201807708SA patent/SG11201807708SA/en unknown
- 2017-03-29 AU AU2017242027A patent/AU2017242027B2/en active Active
- 2017-03-29 IL IL285318A patent/IL285318B/en unknown
- 2017-03-29 EP EP17776574.0A patent/EP3442971A4/en active Pending
- 2017-03-29 CN CN202111035485.4A patent/CN113717170A/zh active Pending
- 2017-03-29 JP JP2019503398A patent/JP6926189B2/ja active Active
- 2017-03-29 RU RU2018132037A patent/RU2738646C2/ru active
- 2017-03-29 CN CN201780033815.1A patent/CN109311870B/zh active Active
- 2017-03-29 BR BR112018070161-0A patent/BR112018070161A2/pt active Search and Examination
- 2017-03-29 CN CN202011582762.9A patent/CN112679495B/zh active Active
- 2017-03-29 CA CA3017388A patent/CA3017388C/en active Active
- 2017-03-29 WO PCT/US2017/024809 patent/WO2017172957A1/en active Application Filing
- 2017-03-29 US US16/086,434 patent/US20190142811A1/en not_active Abandoned
- 2017-03-29 CN CN202011582784.5A patent/CN112745316A/zh active Pending
- 2017-03-29 IL IL295050A patent/IL295050A/en unknown
- 2017-03-29 KR KR1020227016946A patent/KR20220071293A/ko not_active Application Discontinuation
- 2017-03-30 AR ARP170100788A patent/AR108011A1/es unknown
- 2017-03-30 TW TW110145253A patent/TW202235418A/zh unknown
- 2017-03-30 TW TW106110662A patent/TWI746535B/zh active
-
2018
- 2018-09-06 IL IL261654A patent/IL261654B/en unknown
- 2018-09-24 MX MX2022005780A patent/MX2022005780A/es unknown
-
2020
- 2020-05-05 US US16/866,995 patent/US10959989B2/en active Active
- 2020-05-05 US US16/866,900 patent/US11065233B2/en active Active
- 2020-05-05 US US16/867,017 patent/US11065234B2/en active Active
- 2020-12-22 AU AU2020294196A patent/AU2020294196B2/en active Active
-
2021
- 2021-07-06 US US17/305,369 patent/US20210330651A1/en active Pending
- 2021-08-04 JP JP2021127863A patent/JP2021176911A/ja active Pending
-
2022
- 2022-06-09 AU AU2022204025A patent/AU2022204025A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
CR20190478A (es) | Inhibidores de pd-1/pd-l1 | |
PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
MX2020001235A (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. | |
MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
MX2017016376A (es) | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. | |
PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
MX2016010216A (es) | Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos. | |
NZ737399A (en) | Ccr2 modulators | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
PH12017501879A1 (en) | Methods for treating cancer | |
IN2014MU00303A (es) | ||
WO2019023315A3 (en) | RAC INHIBITORS | |
MX2017010422A (es) | Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MX2020000135A (es) | Nuevos compuestos de quinolinona. | |
MY176521A (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer |